ArticleBMC infectious diseases2026
Network analysis of Mycoplasma pneumoniae pneumonia and Epstein-Barr virus co-infection.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMycoplasma pneumoniae(M. pneumoniae) is one of the most frequent causes of community acquired pneumonia (CAP) in children, while Epstein-Barr virus(EBV) infection typically presents subclinical manifestations in immunocompetent children. Although single M. pneumoniae infection is common enough, M. pneumoniae and EBV co-infection has received little attention in clinical practice. It is worth noting that there have been reports of children with Mycoplasma pneumoniae pneumonia(MPP) coinfect with EBV often suffering from more severe lung injury and affecting multiple organ systems. However, the underlying shared targets or pathways remain unclear. This study aims to preliminarily explore the shared targets and pathways of EBV co-infection in pediatric patients with MPP by using network analysis methods.
methodsRelevant targets of MPP and EBV infection were obtained through database mining. The protein-protein interaction(PPI) network construction, Gene Ontology (GO) enrichment analysis and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were employed to identify the shared core target genes and key signalling pathways.
resultsA total of 425 MPP-related target genes and 744 EBV infection-related target genes were obtained, respectively. 113 shared targets were involved in co-infection, and 5 core proteins were obtained through screening, including tumor necrosis factor alpha(TNF-α), interleukin-6(IL-6), interleukin-2(IL-2), interleukin-10(IL-10), and interferon gamma(IFN-γ), which were common inflammatory cytokines. The clinical manifestations both inside and outside the lungs of MPP children with EBV co-infection were more severe than those of children with simple M. pneumoniae infection, which is related to the fact that their shared pathways are mainly enriched in immune responses.
conclusionsThe results indicate that multiple shared inflammatory cytokines and pathways are present between M. pneumoniae and EBV co-infection, confirming that the severe symptoms and poor prognosis of co-infection are related to immune injury. As a network-based bioinformatics analysis, these findings are hypothesis-generating and require further experimental and clinical validation. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.